Inhibitor-Mediated Programming of Glycoforms

The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.

Subsidie
€ 2.998.878
2025

Projectdetails

Introduction

Site-directed mutagenesis revolutionised the study of proteins and enabled the development of protein-based therapeutics. Our long-term vision is to have equivalent impact through the precise manipulation of the glycans (carbohydrates) on cells and recombinant proteins that will enable the discovery and production of the next generation of therapies for cancer, neurodegeneration, and other disease families.

Importance of Glycans

The glycans that are present on most proteins and cells have a substantial impact on their biological functions. However, the untemplated nature of their synthesis leads to inherent heterogeneity in both their structure and activity. This heterogeneity is very difficult to control, making it impossible to generate defined glycan ensembles with optimal activity using current technology.

New Approach

Here we present a radically new approach to the controlled manipulation of glycans that will be the functional equivalent of site-directed mutagenesis for manipulating proteins.

Methodology

We will use the delivery of computationally defined mixtures of enzyme-specific inhibitors to the site of glycan biosynthesis in the cell to tune the activity of glycosyltransferases. Our approach, termed Inhibitor-Mediated Programming of Glycoforms (IMProGlyco), will provide an effective strategy to manipulate the glycosylation machinery and thereby generate proteins with defined ensembles of glycans.

Applications

  1. Therapeutic Proteins and Vaccines: It will enable the production of precision glycan engineered therapeutic proteins and vaccines.
  2. Discovery Science: Moreover, shaping cellular glycan profiles will aid discovery science to uncover glycan functions and improve therapeutic cells, such as those used in Chimeric Antigen Receptors cell Therapy (CAR-T).

Future Prospects

Our technology will be adaptable and expandable into other cell types and organisms, allowing glycan shaping in all areas of eukaryotic cell biology. This will enable new biotechnological applications and fundamental studies of biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.998.878
Totale projectbegroting€ 2.998.878

Tijdlijn

Startdatum1-2-2025
Einddatum31-1-2028
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSITY OF LEEDSpenvoerder
  • UNIVERSITY OF YORK
  • UNIVERSITAET FUER BODENKULTUR WIEN
  • OSLOMET - STORBYUNIVERSITETET
  • OSLO UNIVERSITETSSYKEHUS HF
  • GLYCOSELECT LTD
  • CENTRE FOR PROCESS INNOVATION LIMITED LBG

Land(en)

United KingdomAustriaNorwayIreland

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"

The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.

€ 2.996.550
EIC Pathfinder

Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.

The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.

€ 2.744.300
EIC Pathfinder

Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures

Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.

€ 2.552.277
EIC Pathfinder

Emerging technologies for crystal-based gamma-ray light sources

TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.

€ 2.643.187

Vergelijkbare projecten uit andere regelingen

ERC STG

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

The project aims to engineer CAR-T cells that express an enzyme to de-glycosylate tumor cells, enhancing their efficacy against solid cancers by overcoming immunosuppressive barriers.

€ 1.500.000
ERC COG

Glycan Mimetics for Cell Glycocalyx Reconstitution: a polymer chemist’s approach to fight infection

GLYMCE aims to uncover how carbohydrates influence pathogen interactions to create innovative glycopolymer materials for infection prevention and treatment.

€ 1.994.024
ERC ADG

Targeting of glycosylation pathways to empower CAR-T therapy of solid tumors.

This project aims to enhance CAR-T cell therapy for solid tumors by engineering glycosylation pathways to improve immune response and long-term persistence against immunosuppressive environments.

€ 2.498.435
ERC STG

Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution

Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.

€ 1.500.000